Extended adjuvant aromatase inhibitor therapy in post-menopausal women Journal Article

   


Authors: Schleicher, S. M.; Dickler, M. N.
Article Title: Extended adjuvant aromatase inhibitor therapy in post-menopausal women
Abstract: Purpose of Review: The purpose of this review is to understand the evidence for extending adjuvant aromatase inhibitor (AI) therapy from 5 to 10 years in post-menopausal women with hormone receptor-positive (HR+) breast cancer. Recent Findings: Multiple large trials have investigated this question. The two trials most representative of the dilemma faced in clinical practice are the MA.17R and NSABP-B42 trials, which both investigated the benefit of continuing versus stopping AI therapy beyond 5 years. Both trials showed that extended AI therapy led to a reduction in new or recurrent breast cancers, but had no effect on survival outcomes when death from any cause was included. Summary: The decision to extend AI therapy beyond 5 years remains a personalized one based on a discussion of the projected risk of recurrence, the expected benefits of prolonged AI treatment, and the patient’s ability to tolerate side effects so that quality of life is preserved. © 2017, Springer Science+Business Media, LLC.
Keywords: cancer survival; treatment outcome; fracture; review; cancer recurrence; placebo; cancer combination chemotherapy; monotherapy; treatment duration; cancer adjuvant therapy; recurrence risk; metastasis; breast cancer; aromatase inhibitor; bisphosphonic acid derivative; calcium; exemestane; cancer hormone therapy; death; vitamin d; tamoxifen; clinical decision making; letrozole; premenopause; anastrozole; postmenopause; breast surgery; climacterium; megestrol acetate; extended adjuvant therapy; human; estrogen receptor-positive breast cancer; hormone receptor-positive breast cancer
Journal Title: Current Breast Cancer Reports
Volume: 9
Issue: 4
ISSN: 1943-4588
Publisher: Springer  
Date Published: 2017-12-01
Start Page: 236
End Page: 241
Language: English
DOI: 10.1007/s12609-017-0260-9
PROVIDER: scopus
PMCID: PMC5791913
PUBMED: 29399271
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031935700&doi=10.1007%2fs12609-017-0260-9&partnerID=40&md5=4d6e0be8aa4a11684a9fe5d0d35b6c19
Notes: Review -- Export Date: 2 January 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Maura N Dickler
    262 Dickler
  2. Stephen Matthew Schleicher
    15 Schleicher
Related MSK Work